J&J's New Talc Deal Is $3.5 Billion Smaller Than the One a Judge Threw Out — and Plaintiffs' Lawyers Took It

On July 27, 2026, Johnson & Johnson announced an estimated $5.5 billion to resolve roughly 76,000 ovarian cancer claims — nearly all remaining talc claims, spanning the federal multidistrict litigation in New Jersey and related state court cases. As of July 28, 2026, MDL 2738 alone held 68,435 pending cases out of 71,121 ever filed.

Set that against what came before. The Red River Talc bankruptcy plan — valued at roughly $9 billion and structured to pay out across decades — was rejected on March 31, 2025 by Judge Christopher Lopez of the U.S. Bankruptcy Court for the Southern District of Texas, who found the claimant vote defective. J&J chose not to appeal.

The new structure is faster and smaller: an initial payment of no more than $3 billion in 2027, nothing further due until 2028, and all claims resolved within roughly 18 months rather than stretched over a decade or more. J&J continues to deny wrongdoing.

A dollar promised in 2045 is not a dollar. Stretching roughly $9 billion across decades meant many claimants — women already diagnosed with ovarian cancer — would not live to collect the back end. Compressing $5.5 billion into 18 months changes who actually receives money.

The leverage had also shifted, hard. On July 22, 2026, Magistrate Judge Rukhsanah L. Singh granted a J&J motion requiring plaintiffs to show why the remaining claims should not be dismissed for inability to prove specific causation — the link between this product and this plaintiff's cancer. The motion followed the plaintiffs' withdrawal of two key expert witnesses. Judge Singh characterized it as an opportunity to review the status of the record rather than an immediate dismissal order.

The settlement arrived five days later. A negotiated number in hand is worth more than a larger number on a docket that a court has just invited someone to dismiss.

The deal is conditioned on at least 95% of eligible claimants opting in. Below that threshold it can collapse — and a participation threshold is precisely what sank the last attempt, where the bankruptcy court found the solicitation and voting process defective against the 75% claimant support required under Section 524(g).

The tempting arithmetic: $5.5 billion divided by 76,000 claims is about $72,000 per claim. Treat that as an accounting artifact, not a forecast. Attorney fees and litigation costs come off the top, and mass-tort funds are tiered — by diagnosis, age at diagnosis, duration of exposure and strength of documentation. A well-documented advanced ovarian cancer claim and a thinly documented one do not land in the same tier, and neither lands on the average.

One more limit worth knowing: the agreement covers existing claims only. It does not resolve future lawsuits.

As of publication there is no appointed settlement administrator, no claims website accepting submissions, and no filing deadline — because the settlement is not final. We say this plainly because inaccurate claims are already circulating online, including assertions that a portal opened earlier in 2026 and that a court granted final approval. No talc bankruptcy plan has been given final approval; the most recent one was rejected in March 2025.

This is also an MDL, not a consumer class action. There is no public sign-up. Participation runs through the lawyer already representing a claimant, and firms contact their own clients.

Treat as red flags: any site advertising a talc claim portal or a fixed filing deadline; published payout grids with exact dollar amounts; and anyone requesting an upfront fee or your Social Security number to register. Legitimate settlements never charge you to file.